Anti-DENV-1 Envelope protein E Antibody (1F4)

Catalog No.

RVV19908

Species reactivity

Dengue virus type 1 (strain Nauru/West Pac/1974) (DENV-1), Dengue virus 1

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Target

Genome polyprotein, Envelope protein E

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P17763, G3F5K5

Applications

ELISA

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

1F4

Seroprevalence and Placental Transfer of Zika and Dengue Virus Antibodies in Postpartum Women in Southeast Brazil., PMID:40400258

Quantifying temporal differences in the induction of interferon-mediated signalling observed in a dengue virus 1 human infection model: insights from longitudinal proteome analysis., PMID:40288237

Seropositivity to Dengue, Zika, Yellow Fever, and West Nile Viruses in Senegal, West Africa., PMID:40207881

miRNome analysis reveals mir-155-5p as a protective factor to dengue infection in a resistant Thai cohort., PMID:39976655

The 2023 dengue outbreak in Lombardy, Italy: A one-health perspective., PMID:39755224

Genetic diversity of dengue virus circulating in the Philippines (2014-2019) and comparison with dengue vaccine strains., PMID:39700304

Serotype-Specific Dengue Virus IgG Assay Using EDIII-Based Recombinant Proteins and Its Application in an Endemic Population in Northeast Brazil., PMID:39620308

Dominance of dengue virus serotype-2 in Pakistan (2023-2024): Molecular characterization of the envelope gene and exploration of antiviral targets., PMID:39557198

Genetic and structural characterization of dengue virus involved in the 2023 autochthonous outbreaks in central Italy., PMID:39475407

Envelope domain III E324, E351, and E380 mutations lever adaptive evolution of DENV-1 genotype I., PMID:39230303

Efficacy and safety of Butantan-DV in participants aged 2-59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil., PMID:39116904

Dengue Virus and Zika Virus Seroprevalence in the South Pacific Populations of the Cook Islands and Vanuatu., PMID:38793688

Development of optical and electrochemical immunodevices for dengue virus detection., PMID:38780022

Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults., PMID:38294972

Whole genome sequencing of outbreak strains from 2017 to 2018 reveals an endemic clade of dengue 1 virus in Cameroon., PMID:37933502

Epitope prediction and designing of receptor inhibitor of Dengue Envelope Protein: An in silico approach., PMID:37417165

Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody., PMID:37409936

Evolutionary dynamics of dengue virus in India., PMID:37011104

Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study., PMID:36888687

Evaluation of an Immunoglobulin E Capture Enzyme-Linked Immunosorbent Assay for the Early Diagnosis of Dengue., PMID:36862827

The dengue virus 4 component of NIAID's tetravalent TV003 vaccine drives its innate immune signature., PMID:36734144

Reactivity of DENV-positive sera against recombinant envelope proteins produced in bacteria and eukaryotic cells., PMID:36192522

Clinical Profile and Lab Findings of Dengue Fever in Children Admitted in a Tertiary Care Hospital., PMID:35780359

Suppression of TGF-β/Smad2 signaling by GW788388 enhances DENV-2 clearance in macrophages., PMID:35596058

Differential heterologous neutralisation profile against strains within DENV-3 genotype II., PMID:35225194

Mathematical models for dengue fever epidemiology: A 10-year systematic review., PMID:35219611

Neutralization of Dengue Virus Serotypes by Sera from Dengue-Infected Individuals Is Preferentially Directed to Heterologous Serotypes and Not against the Autologous Serotype Present in Acute Infection., PMID:34696387

Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate., PMID:34475493

Co-Circulation of All Four Dengue Viruses and Zika Virus in Guerrero, Mexico, 2019., PMID:33944623

Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine., PMID:33515283

Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study., PMID:32342848

Aedes aegypti lachesin protein binds to the domain III of envelop protein of Dengue virus-2 and inhibits viral replication., PMID:32141690

Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study., PMID:32124728

Alanine Substitution Inactivates Cross-Reacting Epitopes in Dengue Virus Recombinant Envelope Proteins., PMID:32069839

High correlation between Zika virus NS1 antibodies and neutralizing antibodies in selected serum samples from normal healthy Thais., PMID:31534148

The Dengue ED3 Dot Assay, a Novel Serological Test for the Detection of Denguevirus Type-Specific Antibodies and Its Application in a Retrospective Seroprevalence Study., PMID:30934772

First dengue virus seroprevalence study on Madeira Island after the 2012 outbreak indicates unreported dengue circulation., PMID:30867031

Surveillance for Flaviviruses Near the Mexico-U.S. Border: Co-circulation of Dengue Virus Serotypes 1, 2, and 3 and West Nile Virus in Tamaulipas, Northern Mexico, 2014-2016., PMID:30226141

Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice., PMID:29976679

Molecular characterisation and phylogenetic analysis of dengue outbreak in Pasighat, Arunachal Pradesh, Northeast India., PMID:29735824

In silico prediction of monovalent and chimeric tetravalent vaccines for prevention and treatment of dengue fever., PMID:29497025

Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo., PMID:29367852

Structural Mimicry of the Dengue Virus Envelope Glycoprotein Revealed by the Crystallographic Study of an Idiotype-Anti-idiotype Fab Complex., PMID:28637753

Dengue virus and malaria concurrent infection among febrile subjects within Ilorin metropolis, Nigeria., PMID:28198544

Neutralizing and enhancing antibody responses to five genotypes of dengue virus type 1 (DENV-1) in DENV-1 patients., PMID:27911254

Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies., PMID:27821688

Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies., PMID:27301568

Characterization of two anti-dengue human monoclonal antibodies prepared from PBMCs of patients with dengue illness in Thailand., PMID:27265466

Synthetic B-Cell Epitopes Eliciting Cross-Neutralizing Antibodies: Strategies for Future Dengue Vaccine., PMID:27223692

Characterization of the 2013 dengue epidemic in Myanmar with dengue virus 1 as the dominant serotype., PMID:27154331

Document Download

Anti-DENV-1 Envelope protein E Antibody (1F4).pdf